000130831 001__ 130831
000130831 005__ 20240228145554.0
000130831 0247_ $$2doi$$a10.1186/s13048-017-0365-9
000130831 0247_ $$2pmid$$apmid:29078793
000130831 0247_ $$2pmc$$apmc:PMC5658930
000130831 0247_ $$2altmetric$$aaltmetric:30589168
000130831 037__ $$aDKFZ-2017-05909
000130831 041__ $$aeng
000130831 082__ $$a610
000130831 1001_ $$aKischkel, Frank Christian$$b0
000130831 245__ $$aPrediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test).
000130831 260__ $$aLondon$$bBioMed Central$$c2017
000130831 3367_ $$2DRIVER$$aarticle
000130831 3367_ $$2DataCite$$aOutput Types/Journal article
000130831 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1526386871_1674
000130831 3367_ $$2BibTeX$$aARTICLE
000130831 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130831 3367_ $$00$$2EndNote$$aJournal Article
000130831 520__ $$aIn order to validate if the test result of the Chemotherapy Resistance Test (CTR-Test) is able to predict the resistances or sensitivities of tumors in ovarian cancer patients to drugs, the CTR-Test result and the corresponding clinical response of individual patients were correlated retrospectively. Results were compared to previous recorded correlations.The CTR-Test was performed on tumor samples from 52 ovarian cancer patients for specific chemotherapeutic drugs. Patients were treated with monotherapies or drug combinations. Resistances were classified as extreme (ER), medium (MR) or slight (SR) resistance in the CTR-Test. Combination treatment resistances were transformed by a scoring system into these classifications.Accurate sensitivity prediction was accomplished in 79% of the cases and accurate prediction of resistance in 100% of the cases in the total data set. The data set of single agent treatment and drug combination treatment were analyzed individually. Single agent treatment lead to an accurate sensitivity in 44% of the cases and the drug combination to 95% accuracy. The detection of resistances was in both cases to 100% correct. ROC curve analysis indicates that the CTR-Test result correlates with the clinical response, at least for the combination chemotherapy. Those values are similar or better than the values from a publication from 1990.Chemotherapy resistance testing in vitro via the CTR-Test is able to accurately detect resistances in ovarian cancer patients. These numbers confirm and even exceed results published in 1990. Better sensitivity detection might be caused by a higher percentage of drug combinations tested in 2012 compared to 1990. Our study confirms the functionality of the CTR-Test to plan an efficient chemotherapeutic treatment for ovarian cancer patients.
000130831 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000130831 588__ $$aDataset connected to CrossRef, PubMed,
000130831 7001_ $$aMeyer, Carina$$b1
000130831 7001_ $$aEich, Julia$$b2
000130831 7001_ $$aNassir, Mani$$b3
000130831 7001_ $$aMentze, Monika$$b4
000130831 7001_ $$aBraicu, Ioana$$b5
000130831 7001_ $$0P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aKopp-Schneider, Annette$$b6$$udkfz
000130831 7001_ $$aSehouli, Jalid$$b7
000130831 773__ $$0PERI:(DE-600)2455679-8$$a10.1186/s13048-017-0365-9$$gVol. 10, no. 1, p. 72$$n1$$p72$$tJournal of ovarian research$$v10$$x1757-2215$$y2017
000130831 909CO $$ooai:inrepo02.dkfz.de:130831$$pVDB
000130831 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb6a7a70f976eb8df1769944bf913596$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000130831 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000130831 9141_ $$y2017
000130831 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ OVARIAN RES : 2015
000130831 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130831 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130831 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130831 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000130831 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000130831 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000130831 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130831 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130831 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130831 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130831 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130831 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130831 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000130831 980__ $$ajournal
000130831 980__ $$aVDB
000130831 980__ $$aI:(DE-He78)C060-20160331
000130831 980__ $$aUNRESTRICTED